KR102098998B1 - Medicinal herbs composition for enhancing immune activity - Google Patents

Medicinal herbs composition for enhancing immune activity Download PDF

Info

Publication number
KR102098998B1
KR102098998B1 KR1020180004173A KR20180004173A KR102098998B1 KR 102098998 B1 KR102098998 B1 KR 102098998B1 KR 1020180004173 A KR1020180004173 A KR 1020180004173A KR 20180004173 A KR20180004173 A KR 20180004173A KR 102098998 B1 KR102098998 B1 KR 102098998B1
Authority
KR
South Korea
Prior art keywords
weight
enhancing
immune activity
mushroom
composition
Prior art date
Application number
KR1020180004173A
Other languages
Korean (ko)
Other versions
KR20190086092A (en
Inventor
나창수
손홍석
문양선
Original Assignee
농업회사법인 유한회사 나우리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 농업회사법인 유한회사 나우리 filed Critical 농업회사법인 유한회사 나우리
Priority to KR1020180004173A priority Critical patent/KR102098998B1/en
Publication of KR20190086092A publication Critical patent/KR20190086092A/en
Application granted granted Critical
Publication of KR102098998B1 publication Critical patent/KR102098998B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K97/00Accessories for angling
    • A01K97/22Platforms or seat-boxes specially adapted for angling, e.g. tackle boxes for use as seats
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K97/00Accessories for angling
    • A01K97/04Containers for bait; Preparation of bait
    • A01K97/05Containers for live bait kept in water, e.g. for minnows or shrimps
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K97/00Accessories for angling
    • A01K97/10Supports for rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815Lycium (desert-thorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965Asparagus, e.g. garden asparagus or asparagus fern
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C7/00Parts, details, or accessories of chairs or stools
    • A47C7/62Accessories for chairs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S81/00Tools
    • Y10S81/01Tool-support adjuncts

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 노루궁뎅이버섯, 꽃송이버섯, 홍삼, 복령, 천문동, 맥문동, 구기자, 초석잠, 생지황 및 봉밀을 포함하는 면역활성 증강용 한약재 조성물에 관한 것으로, 본 발명의 면역활성 증강용 한약재 조성물은 염증성 사이토카인(cytokine)인 TNF-α(tumor necrosis factor α), IL-2 및 IL-6을 감소시키고 면역항체인 면역글로불린 E(Immunoglobulin E, IgE)를 감소시키는 효과가 있을 뿐만 아니라 백혈구(White Blood Cell, WBC), 호중구(neutrophils), 림프구(lymphocyte), 및 단핵구(monocyte)를 증가시키는 효과가 있다.The present invention relates to a medicinal herb composition for enhancing immune activity, including roe deer mushroom, zinnia mushroom, red ginseng, Bokryeong, Cheonmun-dong, McMun-dong, Gojija, Chosukjam, raw red yeast, and bee-mil, and the herbal composition for enhancing immune activity of the present invention is inflammatory In addition to reducing the cytokine (cytokine), TNF-α (tumor necrosis factor α), IL-2 and IL-6, and immunoglobulin E (Immunoglobulin E, IgE), as well as reducing white blood cells (White Blood) Cell, WBC), neutrophils (neutrophils), lymphocytes (lymphocytes), and monocytes (monocytes) to increase the effect.

Description

면역활성 증강용 한약재 조성물{Medicinal herbs composition for enhancing immune activity}Medicinal herbs composition for enhancing immune activity

본 발명은 면역활성 증강용 한약재 조성물에 관한 것으로, 보다 상세하게는 노루궁뎅이버섯, 꽃송이버섯, 홍삼, 복령, 천문동, 맥문동, 구기자, 초석잠, 생지황 및 봉밀을 포함하는 면역활성 증강용 한약재 조성물에 관한 것이다.The present invention relates to an herbal composition for enhancing immune activity, and more specifically, to a medicinal herb composition for enhancing immune activity, including roe deer mushroom, red oyster mushroom, red ginseng, boknyeong, astronomical dong, maekmun-dong, goji berry, chosukjam, raw green beans and beeswax. It is about.

건강에 대한 관심이 많아지면서 면역력을 향상시킬 수 있는 식품이나 제제, 이의 처리 방법에도 관심도가 높아지고 있다.As interest in health increases, interest in foods, preparations, and treatment methods for improving immunity is also increasing.

경옥고(瓊玉膏)는 한의학상 보약 처방의 하나로, 인삼, 백복령, 생지황, 봉밀의 약재로 구성된다. 경옥고는 정(精)을 채우고 수(髓)를 보하며, 모발을 검게 하고 치아를 나게 하며, 만신(萬神)이 구족(俱足)하여 백병을 제거한다고 되어 있다. 경옥고에 천문동, 맥문동, 구기자를 더 넣은 것이 익수영진고(益壽永眞膏)이다. 익수영진고는 경옥고에 보음(補陰)시킬 수 있는 재료가 추가되어 있어서 기를 돋우고 음기를 길러주는(益氣養陰) 효과를 증강한 제제이다(Kim MD. The literature study on the efficacy and manufacturing process of Gyeongoggo. J Oriental Medical Classics. 2011 ; 24(2) : 51-64). 경옥고와 익수영진고는 허(虛)한 것을 보(補)하는 대표적인 고(膏) 형태의 제제이다.Gyeongokgo (瓊 玉 膏) is one of the herbal medicine prescriptions, and consists of ginseng, baekbokryong, saengjihwang, and bongmil. It is said that Gyeongokgo fills the jeong and replenishes the water, blackens the hair, makes the teeth come out, and removes the disease by making the Manshin (구 神) prosperous. Iksuyoungjingo (것이 永 眞 膏) is the addition of cheonmun-dong, macmun-dong, and goji berry to Gyeongok High School. Iksuyoungjingo is a preparation that enhances the effect of stimulating and nurturing genitals by adding materials that can be bore in Gyeongokgo (Kim MD.The literature study on the efficacy and manufacturing process of Gyeongoggo. J Oriental Medical Classics. 2011; 24 (2): 51-64). Gyeongokgo and Iksuyoungjingo are representative high-form preparations that complement the deficiency.

경옥고 또는 익수영진고의 유효성을 강화하기 위하여 기능성 원료 또는 다른 약재를 첨가하는 기술들이 개발되고 있다. 한국등록특허 제10-1198211호(2012.11.07.)에는 해삼을 이용한 경옥고의 제조방법이 개시되어 있는데, 지황 엑기스, 홍삼분말 및 백복령 분말을 혼합한 혼합물에 내장이 분리된 해삼의 육부분을 데친 후 건조 및 분쇄하여 얻어진 해삼분말을 혼합하여 이루어진 경옥고를 제공한다. 한국등록특허 제10-1016195호(2011.02.22.)에는 천마경옥고가 개시되어 있는데, 인삼 및 백복령을 분쇄하고, 생지황 즙을 내며, 인삼분말 및 백복령 분말을 상기 생지황즙 및 천마교이에 침윤시켜 냉장보관하고 중탕, 냉각 및 중탕하여 찹쌀로 당화액을 제조하는 과정에 상기 천마교이를 첨가하여 제조되는 천마경옥고를 제공한다.In order to enhance the effectiveness of gyeongokgo or iksuyoungjingo, techniques for adding functional raw materials or other medicines have been developed. Korean Registered Patent No. 10-1198211 (2012.11.07.) Discloses a method of manufacturing gyeongokgo using sea cucumber, which boils the fleshy part of sea cucumber in which the gut is separated in a mixture of Chihwang extract, red ginseng powder and Baekboknyeong powder. After drying and pulverization to provide a jadeite made by mixing the sea cucumber powder obtained. Korean Registered Patent No. 10-1016195 (2011.02.22.) Discloses Cheonma gyeongokgo, which crushes ginseng and Baekbokryeong, produces raw saengwanghwang juice, and infiltrates the ginseng powder and Baegbokgryeong powder into the saengjihwang juice and Cheongmagyi and refrigerates It provides a cheonma gyeongokgo prepared by adding the cheonma gyo during the process of preparing saccharified solution with glutinous rice by storing, immersing, cooling and tangling.

이에, 본 발명의 발명자는 익수영진고(홍삼, 백복령, 생지황즙, 봉밀, 천문동, 맥문동, 구기자)를 이루는 조성물에 추가 원료로 노루궁뎅이버섯, 꽃송이버섯 및 초석잠을 포함하는 한약재 조성물이 면역 활성을 증진시킴을 확인하고 본 발명에 이르렀다.Thus, the inventors of the present invention, as an additional raw material to the composition constituting Iksuyoungjingo (red ginseng, Baekbokryeong, raw sake juice, beekmil, cheonmun-dong, maekmun-dong, gojija), the herbal composition containing roe deer mushroom, zinnia mushroom, and zinnia sleep is immune active It has been confirmed that it promotes and has led to the present invention.

한국등록특허 제10-1198211호(2012.11.07.)Korean Registered Patent No. 10-1198211 (2012.11.07.) 한국등록특허 제10-1016195호(2011.02.22.)Korean Registered Patent No. 10-1016195 (2011.02.22.)

본 발명의 목적은 면역활성 증강용 한약재 조성물을 제공하는 것이다.An object of the present invention is to provide an herbal composition for enhancing immune activity.

본 발명의 다른 목적은 면역활성 증강용 한약재 고(膏) 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for preparing an herbal medicine for enhancing immune activity.

상기한 목적을 달성하기 위하여 본 발명은, 노루궁뎅이버섯, 꽃송이버섯, 홍삼, 복령, 천문동, 맥문동, 구기자, 초석잠, 생지황 및 봉밀을 포함하는 면역활성 증강용 한약재 조성물을 제공한다.In order to achieve the above object, the present invention provides a herbal medicine composition for enhancing immune activity, including roe deer mushroom, matsutake mushroom, red ginseng, bokryeong, cheonmun-dong, maekmun-dong, goji berry, chosukjam, saengjihwang, and beekmil.

본 발명의 일 실시예에 있어서, 상기 복령은 백복령, 복령피 또는 이들의 혼합일 수 있다.In one embodiment of the present invention, the bokryeong may be baekbokryeong, bokryeongpi or a mixture thereof.

본 발명의 일 실시예에 있어서, 상기 생지황은 생지황 즙액, 지황박 또는 이들의 혼합일 수 있다.In one embodiment of the present invention, the raw geohwang may be raw geohwang juice, geohwang foil or a mixture thereof.

본 발명의 일 실시예에 있어서, 상기 면역활성 증강용 한약재 조성물은 조성물 총 중량에 대하여 노루궁뎅이버섯 1 내지 7 중량%, 꽃송이버섯 0.5 내지 5 중량%, 홍삼 2 내지 10 중량%, 복령 5 내지 15 중량%, 천문동 0.5 내지 5 중량%, 맥문동 0.5 내지 5 중량%, 구기자 0.5 내지 5 중량%, 초석잠 0.5 내지 5 중량%, 생지황 30 내지 53 중량% 및 봉밀 25 내지 40 중량%를 포함할 수 있다.In one embodiment of the present invention, the composition for medicinal herbs for enhancing immune activity is 1 to 7% by weight of yellow beetle mushroom, 0.5 to 5% by weight of zinnia mushroom, 2 to 10% by weight of red ginseng, 5 to 15% of bokkryeong Weight%, 0.5 to 5% by weight, munmundong 0.5 to 5% by weight, 0.5 to 5% by weight goji wolfberry, 0.5 to 5% by weight choknapjam, 30 to 53% by weight of raw green beans and 25 to 40% by weight sealing .

본 발명의 일 실시예에 있어서, 상기 면역활성 증강용 한약재 조성물이 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰(Leuconostoc mesenteroides subsp. dextranicum) 균주로 발효된 것일 수 있다.In one embodiment of the present invention, the herbal composition for enhancing the immune activity may be fermented with a Leuconostoc mesenteroides subsp. Dextranicum strain.

본 발명의 일 실시예에 있어서, 상기 발효는 33 내지 38℃에서 3 내지 7일 동안 실시하는 것일 수 있다.In one embodiment of the invention, the fermentation may be carried out at 33 to 38 ℃ for 3 to 7 days.

본 발명의 일 실시예에 있어서, 상기 면역활성 증강용 한약재 조성물이 화장품, 건강보조식품 또는 약학조성물에 포함되어 사용될 수 있다.In one embodiment of the present invention, the herbal composition for enhancing immune activity may be included in cosmetics, health supplements, or pharmaceutical compositions.

본 발명의 일 실시예에 있어서, 상기 면역활성 증강용 한약재 조성물이 연조엑스, 환, 정 또는 고(膏)의 제형으로 제조될 수 있다.In one embodiment of the present invention, the herbal composition for enhancing immune activity may be prepared in a soft extract, pill, tablet or high dosage form.

본 발명의 다른 목적을 달성하기 위하여 본 발명은 상기 면역활성 증강용 한약재 조성물을 중탕법을 이용하여 면역활성 증강용 한약재 고(膏) 제조방법을 제공한다.In order to achieve another object of the present invention, the present invention provides a method of manufacturing a high-medicinal herb for enhancing immune activity by using the Chinese herbal medicine method for enhancing the immuno-activity.

본 발명의 면역활성 증강용 한약재 조성물은 염증성 사이토카인(cytokine)인 TNF-α(tumor necrosis factor α), IL-2 및 IL-6을 감소시키고 면역항체인 면역글로불린 E(Immunoglobulin E, IgE)를 감소시키는 효과가 있을 뿐만 아니라 백혈구(White Blood Cell, WBC), 호중구(neutrophils), 림프구(lymphocyte), 및 단핵구(monocyte)를 증가시키는 효과가 있다.The herbal composition for enhancing immune activity of the present invention reduces inflammatory cytokines, TNF-α (tumor necrosis factor α), IL-2 and IL-6, and immunoglobulin E (Immunoglobulin E, IgE), an immune antibody. In addition to having a reducing effect, white blood cells (WBC), neutrophils (neutrophils), lymphocytes (lymphocytes), and monocytes (monocytes) increase the effect.

또한, 본 발명의 면역활성 증강용 한약재 조성물은 내산성 및 내답증성이 우수하고 대장균과 같은 유해균에 대한 항균 활성이 있는 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰(Leuconostoc mesenteroides subsp. dextranicum) 균주를 이용하여 발효됨으로써, 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰 균주가 위와 소화관을 거쳐 장까지 생존하여 장내 유해 미생물을 억제하고 병원성 미생물 감염을 예방할 수 있어 장 건강에 도움이 되고 프로바이오틱스(probiotics)로 이용될 수 있다. In addition, the herbal composition for enhancing the immune activity of the present invention is excellent in acid resistance and sufficiency and has antibacterial activity against harmful bacteria such as E. coli Leuconostoc mesenteroides subsp. Dextranicum strain By being fermented using, Leukonostock mesenteroides subspheris dextranicum strain survives through the stomach and digestive tract to the intestine, thereby suppressing harmful microorganisms in the intestine and preventing pathogenic microbial infections, which is beneficial for gut health and probiotics ( probiotics).

본 발명의 면역활성 증강용 한약재 조성물은 화장품, 건강보조식품 또는 약학 조성물에 포함되어 사용될 수 있다.The herbal composition for enhancing immune activity of the present invention may be used in cosmetics, health supplements, or pharmaceutical compositions.

본 발명의 면역활성 증강용 한약재 조성물은 기존에 폐기 처분되던 꽃송이버섯 기부, 복령피 또는 지황박을 활용함으로써 원가를 절감할 수 있을 뿐만 아니라 쓰레기 발생을 줄여 환경오염을 방지할 수 있다.The herbal composition for enhancing immune activity of the present invention can not only reduce the cost but also prevent the environmental pollution by reducing the generation of waste by utilizing the donation of blossom mushrooms that were previously disposed of, Bokryeongpi or Chihwang.

도 1은 본 발명에서 최종 선발된 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰(Leuconostoc mesenteroides subsp. dextranicum) 균주의 16S rRNA 염기서열 분석에 따른 계통발생 분석도이다.
도 2는 본 발명의 면역 증강 조성물이 쥐의 혈청 내 TNF-α 함량에 미치는 영향을 나타내는 그래프이다.
도 3은 본 발명의 면역 증강 조성물이 쥐의 혈청 내 IL-2 함량에 미치는 영향을 나타내는 그래프이다.
도 4는 본 발명의 면역 증강 조성물이 쥐의 혈청 내 IL-6 함량에 미치는 영향을 나타내는 그래프이다.
도 5는 본 발명의 면역 증강 조성물이 쥐의 혈청 내 IgE 함량에 미치는 영향을 나타내는 그래프이다.
도 6은 본 발명의 면역 증강 조성물이 쥐의 비장 무게에 미치는 영향을 나타내는 그래프이다.
도 7은 본 발명의 면역 증강 조성물이 쥐의 혈액 내 백혈구에 미치는 영향을 나타내는 그래프이다.
도 8은 본 발명의 면역 증강 조성물이 쥐의 혈액 내 적혈구에 미치는 영향을 나타내는 그래프이다.
도 9는 본 발명의 면역 증강 조성물이 쥐의 증체량에 미치는 영향을 나타내는 그래프이다.
도 10은 본 발명의 면역 증강 조성물이 쥐의 혈청 아미노기 전이효소(aminotransferase) 함량에 미치는 영향을 나타내는 그래프이다.
1 is a phylogenetic analysis according to 16S rRNA sequencing of Leuconostoc mesenteroides subsp. Dextranicum strains finally selected in the present invention.
Figure 2 is a graph showing the effect of the immune enhancing composition of the present invention on the TNF-α content in the serum of rats.
Figure 3 is a graph showing the effect of the immune-enhancing composition of the present invention on the serum IL-2 content of rats.
Figure 4 is a graph showing the effect of the immune-enhancing composition of the present invention on the serum IL-6 content of rats.
5 is a graph showing the effect of the immune enhancing composition of the present invention on the IgE content in the serum of rats.
6 is a graph showing the effect of the immune enhancing composition of the present invention on the spleen weight of rats.
7 is a graph showing the effect of the immune enhancing composition of the present invention on leukocytes in rat blood.
8 is a graph showing the effect of the immune enhancing composition of the present invention on red blood cells in rat blood.
9 is a graph showing the effect of the immune enhancing composition of the present invention on the weight gain of rats.
10 is a graph showing the effect of the immune enhancing composition of the present invention on the serum aminotransferase content of rats.

본 발명의 면역활성 증강용 한약재 조성물은 노루궁뎅이버섯, 꽃송이버섯, 홍삼, 복령, 천문동, 맥문동, 구기자, 초석잠, 생지황 및 봉밀을 포함하는 것을 특징으로 한다.Herbal medicine composition for enhancing the immune activity of the present invention is characterized in that it contains roe deer mushroom, matsutake mushroom, red ginseng, Bokryeong, Cheonmun-dong, McMun-dong, goji berry, Chosukjam, saengjihwang, and beeswak.

본 발명에 있어서, 노루궁뎅이버섯, 꽃송이버섯, 홍삼, 복령, 천문동, 맥문동, 구기자 및 초석잠은 분말 형태가 바람직하게 사용된다.In the present invention, the powder form of roe, mushroom, red ginseng, Bokryeong, astronomical dong, McMun-dong, goji berry, and Chomnapjam are preferably used.

본 발명에 있어서, 상기 면역활성 증강용 한약재 조성물은 조성물 총 중량에 대하여 노루궁뎅이버섯 1 내지 7 중량%, 꽃송이버섯 0.5 내지 5 중량%, 홍삼 2 내지 10 중량%, 복령 5 내지 15 중량%, 천문동 0.5 내지 5 중량%, 맥문동 0.5 내지 5 중량%, 구기자 0.5 내지 5 중량%, 초석잠 0.5 내지 5 중량%, 생지황 30 내지 53 중량% 및 봉밀 25 내지 40 중량%를 포함하는 것이 바람직하다.In the present invention, the composition for medicinal herbs for enhancing immunity activity is 1 to 7% by weight of yellow beetroot mushroom, 0.5 to 5% by weight of zinnia mushroom, 2 to 10% by weight of red ginseng, 5 to 15% by weight of bokryeong, 5 to 15% by weight, cheonmundong It is preferable to include 0.5 to 5% by weight, 0.5 to 5% by weight of McMundong, 0.5 to 5% by weight of goji berry, 0.5 to 5% by weight of Chomnapam, 30 to 53% by weight of raw sulcus, and 25 to 40% by weight of sealed wheat.

본 발명에 있어서, 상기 꽃송이버섯은 꽃송이버섯의 자실체나 기부(stipe) 단독 또는 이들이 혼합되어 사용될 수 있다.In the present invention, the blossom mushrooms may be used alone or as a mixture of the fruit body or the stem of the blossom mushroom.

상기 꽃송이버섯 기부는 수확한 꽃송이버섯에서 자실체와 분리하는 과정을 거쳐 수득된다. 상기 꽃송이버섯이 톱밥재배 방법으로 수확된 경우에, 상기 자실체와 분리된 기부는 건식분쇄기로 톱밥을 제거하는 전처리 과정을 거친 것이 바람직하다.The base of the blossom mushroom is obtained through a process of separating the fruit from the harvested blossom mushroom. When the mushrooms are harvested by the sawdust cultivation method, it is preferable that the base separated from the fruiting body has undergone a pre-treatment process for removing sawdust with a dry grinder.

본 발명에 있어서, 상기 복령은 백복령, 복령피 또는 이들이 혼합되어 사용될 수 있다. 백복령과 복령피가 혼합되어 사용될 때는 조성물 총 중량에 대하여 백복령 3 내지 13 중량%, 복령피 0.5 내지 5 중량% 포함되는 것이 바람직하다.In the present invention, the Bokryeong may be used in Baekbokyeong, Bokryeongpi or a mixture thereof. When Baeknyeongnyeong and Boknyeongpi are used in combination, it is preferable to contain 3 to 13% by weight of Baengnyeongnyeong and 0.5 to 5% by weight of Boknyeongpi based on the total weight of the composition.

본 발명에 있어서, 상기 생지황은 생지황 즙액, 지황박 또는 이들이 혼합되어 사용될 수 있다. 상기 생지황을 압착하여 액상으로 나오는 것이 생지황 즙액이고, 압착하여 잔사로 남는 것이 지황박이다. 생지황 즙액과 지황박이 혼합되어 사용될 때는 조성물 총 중량에 대하여 생지황 즙액 25 내지 40 중량%, 지황박 10 내지 25 중량% 포함되는 것이 바람직하다.In the present invention, the raw geohwang may be used in combination with raw geohwang juice, geohwang foil or these. It is squeezed raw saenghwang and the raw saenghwang juice is squeezed out and left as a residue is jihwang foil. When used in a mixture of raw aquatic sulfur juice and citrine foil, it is preferable to include 25 to 40% by weight raw aquatic citrate juice and 10 to 25% by weight citrate foil based on the total weight of the composition.

본 발명에 있어서, 상기 면역활성 증강용 한약재 조성물은 조성물 총 중량에 대하여 노루궁뎅이버섯 1 내지 7 중량%, 꽃송이버섯 0.5 내지 5 중량%, 홍삼 2 내지 10 중량%, 백복령 3 내지 13 중량%, 복령피 0.5 내지 5 중량%, 천문동 0.5 내지 5 중량%, 맥문동 0.5 내지 5 중량%, 구기자 0.5 내지 5 중량%, 초석잠 0.5 내지 5 중량%, 생지황 즙액 25 내지 40 중량%, 지황박 10 내지 25 중량% 및 봉밀 25 내지 40 중량%를 포함할 수 있다.In the present invention, the composition for medicinal herbs for enhancing the immune activity is 1 to 7% by weight of yellow beetroot mushrooms, 0.5 to 5% by weight of zinnia mushrooms, 2 to 10% by weight of red ginseng, 3 to 13% by weight of Baekbokryeong, Bokryeongpi 0.5 to 5% by weight, 0.5 to 5% by weight in Astronomical Building, 0.5 to 5% by weight in McMundong, 0.5 to 5% by weight wolfberry, 0.5 to 5% by weight, Chomyeonjam 25 to 40% by weight, 10 to 25% by weight of yellow citrine juice And 25-40% by weight of sealing.

한편, 본 발명의 면역활성 증강용 한약재 조성물은 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰(Leuconostoc mesenteroides subsp. dextranicum) 균주로 발효될 수 있다.On the other hand, the herbal composition for enhancing the immune activity of the present invention may be fermented into Leuconostoc mesenteroides subsp. Dextranicum strain.

본 발명에 있어서, 상기 발효는 33 내지 38℃에서 3 내지 7일 동안 실시되는 것이 바람직하고, 36 내지 37℃에서 4 내지 6일 동안 실시되는 것이 더 바람직하다.In the present invention, the fermentation is preferably performed for 3 to 7 days at 33 to 38 ° C, and more preferably for 4 to 6 days at 36 to 37 ° C.

본 발명의 면역활성 증강용 한약재 조성물은 연조엑스, 환, 정 또는 고(膏)의 제형으로 제조될 수 있다.The herbal composition for enhancing the immune activity of the present invention may be prepared in a soft extract, pill, tablet or high dosage form.

특히, 본 발명의 면역활성 증강용 한약재 조성물은 중탕법(double boiling method)을 이용하여 고(膏)의 제형으로 제조될 수 있다.In particular, the herbal composition for enhancing immune activity of the present invention may be prepared in a high dosage form using a double boiling method.

복령은 담자균류 민주름버섯목 구멍장이버섯과의 버섯으로 소나무 등의 나무뿌리에 기생한다. 버섯갓 표면은 적갈색, 담갈색, 흑갈색으로 꺼칠꺼칠한 편이며 살은 흰색이고 점차 담홍색으로 변한다. 흰색인 것을 백복령(白茯笭), 붉은색인 것을 적복령(赤茯笭)이라 한다. 복령의 약리작용으로는 이뇨작용, 억균작용, 장관이완작용, 궤양예방효과, 혈당강하작용, 심장수축력 증가, 면역증강작용, 항종양작용 등이 알려져 있다.Bokryeong is a mushroom of the genus genus Mushrooms of the genus Dermatophyte, which is parasitic on the roots of pine trees. The surface of the mushroom shade is reddish brown, light brown, and dark brown. The flesh is white and gradually turns pink. The white one is called Baekbokryeong, and the red one is called Jeokbokryeong. As the pharmacological action of Bokryeong, diuretic action, bactericidal action, relaxation of the intestinal tract, ulcer prevention effect, hypoglycemic action, increased cardiac contractility, immune-enhancing action, and anti-tumor action are known.

복령피는 복령 전체 중량 대비 20% 정도에 달한다. 보통 복령피는 버려지고 있는 상황이나 복령외피 추출물이 생체 내에서 조절성 T세포를 유도해 알레르기를 억제할 수 있음이 보고된 바 있다 . Bokryeongpi is about 20% of the total weight of Bokryeong. Normally, it has been reported that the bokryongpi can be suppressed in allergies by inducing conditioned T cells in vivo.

노루궁뎅이버섯은 여름에서 가을까지 졸참나무나 떡갈나무 등 활엽수의 줄기에 자라고 리그닌 성분이 있어 목재 백색 부후성 버섯이다. 대부분의 버섯에는 활성 다당이 최대 2종류이나 노루궁뎅이버섯은 5종류의 활성 다당을 함유하여 탁월한 항암효과를 발휘한다. 또한 노루궁뎅이버섯은 위벽을 둘러싼 혈관을 강화시켜 소화기 질환에도 좋으며, 치매 예방과 당뇨병 개선에도 효과가 있다는 연구 결과가 발표되었다. 더불어 만성 장염 개선, 면역 기능 증대, 치매 억제 등의 효능도 있고 낮은 칼로리와 풍부한 식이섬유 등으로 인해 건강 식재로 각광받고 있다. Roe deer mushroom is a white, white, thick mushroom that grows on the trunks of broad-leaved trees, such as oak and oak trees, from summer to autumn. Most mushrooms have up to two types of active polysaccharides, but roe deer mushrooms contain five types of active polysaccharides, which exert excellent anti-cancer effects. In addition, research results have shown that roe deer mushroom is good for digestive diseases by strengthening blood vessels surrounding the stomach wall, and is also effective in preventing dementia and improving diabetes. In addition, it has the effects of improving chronic enteritis, increasing immune function, and suppressing dementia, and has been spotlighted as a healthy food due to its low calorie and abundant dietary fiber.

꽃송이 버섯은 베타글루칸의 함량이 건조 중량의 40% 이상으로 높다. 베타글루칸은 다당류의 일종으로 세포벽, 버섯류, 곡류 등에 존재하는 물질로 암세포를 직접 공격하지 않고 비특이적 면역반응으로 인간의 정상 세포의 면역기능을 활성화시켜 암세포의 증식과 재발을 억제하고 대식세포를 활성화시켜 암세포가 있는 체내로 들어가 여러 가지 사이토카인의 분비를 촉진시킴으로써 면역세포인 T세포와 B세포의 면역기능을 활성화시켜준다. 꽃송이버섯의 주요성분인 베타글루칸은 일반적인 방법으로는 효과적인 섭취나 수화하는 것에 한계가 있으므로 본 발명에서 꽃송이버섯을 분쇄할 때 입자크기를 200~440 메쉬로 실시하는 것이 바람직하다.Blossom mushrooms have a high beta-glucan content of at least 40% of the dry weight. Beta-glucan is a polysaccharide, a substance that exists in cell walls, mushrooms, and grains. It does not directly attack cancer cells, but activates the immune function of normal cells in humans with a non-specific immune response, suppresses the proliferation and recurrence of cancer cells, and activates macrophages. It enters the body with cancer cells and promotes the secretion of various cytokines, thereby activating the immune function of immune cells T cells and B cells. Beta glucan, a major component of the blossom mushroom, has a limitation in effective intake or hydration in a general way, so it is preferable to perform a particle size of 200 to 440 mesh when crushing the blossom mushroom in the present invention.

초석잠은 쌍떡잎식물 통화식물목 꿀풀과에 속하는 여러해살이풀로, 뇌 기능을 활성화시켜주는 페닐에타노이드라는 성분이 함유되어 있고, 치매를 예방할 수 있는 콜린 성분이 풍부하게 들어 있다. 초석잠은 부종이나 뇌졸증을 예방하는데도 도움을 주며, 혈액 순활을 원활하게 해주므로 간경화와 동맥경화를 개선하고 지방간의 형성을 억제해준다. 또한 지혈과 종기를 가시게 해주는 효능이 있고, 감기를 비롯해 두통·인후염·기관지염 등에도 효과가 있다.Cho-Zam-Jam is a perennial plant belonging to the family of honeybees of the dicotyledonous plant, contains a component called phenylethanoid, which activates brain function, and is rich in choline that can prevent dementia. Chorus sleep also helps to prevent edema and stroke, and improves liver cirrhosis and arteriosclerosis and suppresses the formation of fatty liver by smoothing blood circulation. In addition, it has the effect of helping to stop bleeding and boils, and is also effective for headaches, sore throat, and bronchitis, including colds.

이하, 하기 실시예를 통하여 본 발명의 면역활성 증강용 한약재 조성물을 보다 자세하게 설명한다. Hereinafter, the herbal composition for enhancing the immune activity of the present invention through the following examples will be described in more detail.

<실시예 1> 한약재 조성물 발효에 적합한 미생물 선발<Example 1> Selection of microorganisms suitable for fermentation of herbal composition

1-1. 천연물로부터 균주 분리1-1. Strain separation from natural products

총 17종(배추김치 6종, 갓김치 3종, 동치미 3종, 총각김치, 열무김치, 오이피클, 매실액, 요구르트)의 발효식품을 시료로 사용하였다. 상기 발효식품으로부터 미생물을 분리하기 위해 각 시료를 십진 희석하여 Lactobacilli MRS agar(Difco Co., USA)에 도말(塗抹)하고 37℃에서 2일간 배양하여 무작위적으로 유산균을 1차 분리하고 분리한 유산균은 계대 배양하여 4℃에 보관하며 사용하였다.A total of 17 fermented foods (6 kinds of cabbage kimchi, 3 kinds of fresh kimchi, 3 kinds of Dongchimi, bachelor kimchi, radish kimchi, cucumber pickle, plum liquid, yogurt) were used as samples. In order to separate microorganisms from the fermented food, each sample is diluted in decimal and smeared on Lactobacilli MRS agar (Difco Co., USA) and incubated at 37 ° C for 2 days to randomly separate and separate lactic acid bacteria. Silver was passaged and stored at 4 ° C for use.

1-2. 발효 스타터에 적합한 유산균 분리1-2. Separation of lactic acid bacteria suitable for fermentation starters

MRS agar에서 분리한 균주 중 산 생성 능력이 있는 균주를 확인하기 위하여 pH indicator인 0.006% BCP(Bromocresol Purple, Sigma, USA)를 포함한 MRS 평판배지를 이용하여 유산균을 분리하고, BCP의 보라색 배지가 노란색으로 변하는 군집을 확인하여 순수한 균주를 얻을 때까지 반복하여 유산균을 분리하였다.Among the strains isolated from MRS agar, lactic acid bacteria are separated using MRS plate medium containing pH6, which is a pH indicator of 0.006% BCP (Bromocresol Purple, Sigma, USA), and the purple medium of BCP is yellow. Lactobacillus was isolated repeatedly until a pure strain was obtained by confirming the colonies changing to.

1-3. 내산성 분석1-3. Acid resistance analysis

내산성을 분석하기 위해 분리한 균주를 0.05 M sodium phosphate 완충용액 pH 7.0과 HCl로 pH 2.0, 4.0으로 조정된 0.05 M sodium phosphate 완충용액에 각각 10% 접종한 후 37℃에서 2시간 진탕 배양한 후 600 nm에서 흡광도 측정하여 생존율(%)을 계산하였다.In order to analyze the acid resistance, the isolates were inoculated 10% in 0.05 M sodium phosphate buffer solution adjusted to pH 2.0 and 4.0 with 0.05 M sodium phosphate buffer solution pH 7.0 and HCl, and then cultured with shaking at 37 ° C for 2 hours, followed by 600 Survivability (%) was calculated by measuring absorbance at nm.

Figure 112018003770369-pat00001
Figure 112018003770369-pat00001

위액의 pH는 금식의 경우 pH 0.78~0.90이지만 음식을 섭취하였을 경우 위의 pH가 2.0~3.0까지 올라가며 음식물이 위를 통과하는 시간은 2~4시간이다. 프로바이오틱스로서의 효과를 나타내기 위해서는 pH 3 이하에서 생존하여 위를 거쳐 소장 내로 도달하여야 한다. pH 2에서의 생존율이 70% 이상인 균주를 선발하였다. The pH of gastric juice is pH 0.78 to 0.90 for fasting, but when food is consumed, the pH of the stomach rises to 2.0 to 3.0 and the time for food to pass through the stomach is 2 to 4 hours. In order to show the effect as a probiotic, it must survive below pH 3 and reach the small intestine through the stomach. Strains having a survival rate of 70% or more at pH 2 were selected.

1-4. 내담즙성 분석1-4. Bile resistance analysis

내담즙성을 분석하기 위해 분리한 균주를 Lactobacilli MRS broth와 0.45 μm membrane filter로 여과된 0.3%(w/v) oxgall이 첨가된 MRS broth에 10% 접종하여 37℃에서 8시간 배양한 후 600 nm에서 흡광도 측정하여 생존율(%)을 계산하였다.In order to analyze the bile resistance, the isolates were inoculated 10% in 0.3% (w / v) oxgall added with Lactobacilli MRS broth and 0.45 μm membrane filter, and incubated at 37 ° C. for 8 hours, followed by incubation at 37 ° C. for 600 hours. The absorbance was measured at and the survival rate (%) was calculated.

Figure 112018003770369-pat00002
Figure 112018003770369-pat00002

1-5. 대장균(E. coli)에 대한 항균 활성1-5. Antibacterial activity against E. coli

항균력 검색에 사용한 균주는 평판배지에 배양된 균주 2-3 백금이를 취해 10 mL nutrient broth의 균 생육 액체배지에 접종하고 37℃에서 24시간 배양하여 활성화시킨 후 시험균액 0.2 mL를 무균적으로 첨가하여 기층용 배지위에 고르게 펴지도록 멸균된 유리막대로 도포한 뒤 Piddok의 paper disc에 의한 한천배지 확산법(disc plate method)으로 측정하였다.The strain used for screening for antibacterial activity was obtained by inoculating the culture medium of 2-3 mL of cultured on a plate medium and inoculating it into a 10 mL nutrient broth bacterial growth liquid medium, incubating at 37 ° C. for 24 hours, and then activating 0.2 mL of the test solution. Then, it was coated with a sterilized glass rod to spread evenly on the medium for the base layer, and then measured by agar plate diffusion method using a paper disc of Piddok.

1-6. 선발 균주 동정(identification)1-6. Identification of selected strains

내산성, 내담즙성 및 항균활성 결과를 종합하였을 때 가장 효율이 우수한 5-1 균주를 최종 선발하고 최종 선발된 균주를 16S rRNA partiall sequencing에 의해 분석하였다. 도 1에 본 발명에서 최종 선발된 균주의 16S rRNA 염기서열 분석에 따른 계통발생 분석도가 제시되어 있다. 미생물 동정 결과, 최종 선발 균주 5-1은 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰(Leuconostoc mesenteroides subsp. dextranicum) 균주와 99% 유사성을 보인 것으로 확인되었다(한국미생물보존센터). 도 1에서 스케일바(scale bar)는 0.002% 뉴클레오타이드(nucleotide) 차이를 나타낸다.When the results of acid resistance, bile resistance and antibacterial activity were synthesized, the most efficient 5-1 strain was finally selected and the finally selected strain was analyzed by 16S rRNA partiall sequencing. 1 shows a phylogenetic analysis diagram according to 16S rRNA sequencing of the finally selected strain in the present invention. As a result of microbial identification, it was confirmed that the final selection strain 5-1 showed 99% similarity to the Leuconostoc mesenteroides subsp. Dextranicum strain (Korea Microbiological Conservation Center). In FIG. 1, the scale bar represents a 0.002% nucleotide difference.

<실시예 2> 면역활성 증강용 한약재 조성물 제조<Example 2> Preparation of herbal composition for enhancing immune activity

2-1. 재료 준비2-1. Ingredient preparation

꽃송이버섯(Sparassis crispa)은 (영)백아산꽃송이버섯(Hwasun, Korea)에서, 노루궁뎅이버섯(Hericium erinaceus)은 (주)유림바이오(Pyeongteck, Korea)에서 구입하여 사용하였다. 홍삼(Red Ginseng radix), 복령(Poria cocos), 천문동(Asparagi radix), 맥문동(Liriopis tuber), 구기자(Lycii fructus), 초석잠(Stachys sieboldii Miq), 봉밀(Honey)은 한약재유통센터(Hwasun, Korea)와 옴니허브(Daegu, Korea)에서 구입하여 사용하였다. 생지황(Rehmanniae radix)은 생지황영농조합(Geumsan, Korea)에서 구입하였다. 재료는 모두 국내산을 사용하였다. Sparassis crispa was purchased from (Young) Baek-Asan Blossom Mushroom (Hwasun, Korea), and Hericium erinaceus was purchased from Eulim Bio (Pyeongteck, Korea). Ginseng (Red Ginseng radix), Poria cocos (Poria cocos), cheonmundong (Asparagi radix), maekmundong (Liriopis tuber), Goji (Lycii fructus), the cornerstone sleep herbal medicines distribution center (Stachys sieboldii Miq), Honey (Honey) (Hwasun, Korea) and Omni Herb (Daegu, Korea). Rehmanniae radix was purchased from Saengjihwang Farming Association (Geumsan, Korea). All materials were made in Korea.

노루궁뎅이버섯, 꽃송이버섯, 홍삼, 복령, 천문동, 맥문동, 구기자, 초석잠 및 생지황을 초음파 세척기로 세척하였다. 상기 복령은 껍질을 벗겨 복령피(복령원물의 15%)와 백복령(복령원물의 85%)으로 나누었다. 상기 재료 중 고형재료인 노루궁뎅이버섯, 꽃송이버섯, 홍삼, 백복령, 복령피, 천문동, 맥문동, 구기자 및 초석잠을 각각 분쇄하여 미세분말화 하였다. 상기 생지황은 분쇄 후 압착하여 생지황 즙액(착즙율 60%)과 지황박으로 분리하였다.Roe deer mushroom, zinnia mushroom, red ginseng, Bokryeong, Cheonmun-dong, McMun-dong, goji berry, Choseokjam, and raw sulfur were washed with ultrasonic cleaner. The bokryeong was peeled and divided into bokryeongpi (15% of the bokryeong raw material) and white bokryeong (85% of the bokryeong raw material). Among the above-mentioned materials, solid materials such as red beetroot mushroom, matsutake mushroom, red ginseng, Baekbok-ryeong, Bokryeong-pi, cheonmun-dong, maekmun-dong, gojija, and choseokjam were respectively pulverized and finely powdered. The raw turmeric was compressed by crushing and then separated into a raw turmeric juice (60% juice rate) and a crimson foil.

2-2. 면역활성 증강용 한약재 조성물 제조2-2. Preparation of herbal composition for enhancing immune activity

상기에서 준비된 재료를 표 1에 제시된 양으로 혼합하여 면역활성 증강용 한약재 조성물을 제조하였다. The ingredients prepared above were mixed in the amounts shown in Table 1 to prepare an herbal composition for enhancing immune activity.

준비된 재료량(g) 홍삼 900 봉밀 6000 천문동 150 맥문동 150 구기자 300 꽃송이버섯 200 노루궁뎅이버섯 700 초석잠 300 백봉령 1530 생지황 즙액 5760 복령피 270 지황박 3840 20,100
<실시예 3> 면역활성 증강용 한약재 조성물 제조
Prepared material amount (g) Red ginseng 900 Sealing 6000 Astronomical building 150 McMundong 150 Wolfberry 300 Blossom mushroom 200 Roe deer mushroom 700 Sleep 300 Baekbongnyeong 1530 Saengjihwang Juice 5760 Bokryeongpi 270 Jihwang Park 3840 system 20,100
<Example 3> Preparation of herbal composition for enhancing immune activity

삭제delete

실시예 2에서 준비된 재료를 표 1에 제시된 양으로 혼합하여 면역활성 증강용 한약재 조성물을 제조하였다. The ingredients prepared in Example 2 were mixed in the amounts shown in Table 1 to prepare an herbal composition for enhancing immune activity.

<실시예 4> 면역활성 증강용 한약재 조성물 제조<Example 4> Preparation of herbal composition for enhancing immune activity

4-1. 균주 준비4-1. Strain preparation

실시예 1에서 최종 선발된 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰 균주를 MRS 배지에 접종한 후 37℃에서 48시간 동안 전배양시켜 스타터 균주를 준비하였다.A starter strain was prepared by inoculating MRS medium with the Leuconostock mesenteroides subspheris destranicum strain finally selected in Example 1 in MRS medium for 48 hours.

4-2. 면역활성 증강용 한약재 조성물 제조4-2. Preparation of herbal composition for enhancing immune activity

상기에서 준비된 재료를 표 1에 제시된 양으로 혼합하였다. 상기에서 전배양된 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰 균주를 2%(v/v) 접종하여 37℃에서 110시간 동안 발효시켜 면역활성 증강용 한약재 조성물을 제조하였다.The materials prepared above were mixed in the amounts shown in Table 1. A 2% (v / v) inoculation of the pre-cultured Leuconostock mesenteroides subspheris dextranicum strain was fermented at 37 ° C. for 110 hours to prepare an herbal composition for enhancing immune activity.

<실시예 5> 면역활성 증강용 한약재 조성물 제조<Example 5> Preparation of herbal composition for enhancing immune activity

표 1에 제시된 양으로 혼합한 것을 제외하고 실시예 4와 동일한 방법으로 면역활성 증강용 한약재 조성물을 제조하였다.A herbal medicine composition for enhancing immune activity was prepared in the same manner as in Example 4, except that the mixture was mixed in the amounts shown in Table 1.

<실시예 6> 면역 증진 고(膏) 제조<Example 6> Immunity-promoting high production

실시예 2에서 제조된 면역활성 증강용 한약재 조성물을 잘 반죽하여 옹기에 넣었다. 물이 채워진 중탕기에 상기 옹기를 넣었다. 온도측정기(KP3001, Ziraffe, China)를 이용하여 3일 동안 98~102℃로 유지하면서 1차 중탕을 시행하였고, 이때 중탕기에 채워진 물은 옹기가 80% 이상 잠길 수 있게 유지되도록 보충하였다. 1차 중탕이 끝난 후 1일 동안 실온에 방치하면서 1차 숙성 과정을 진행하였다. 이어 1일 동안 1차 중탕과 같은 조건으로 2차 중탕을 시행하였고, 이후 1일 동안 1차 숙성과 같은 조건으로 2차 숙성 과정을 진행하여 면역 증진 고(膏)를 제조하였다(IYG-gami).The herbal composition for enhancing immune activity prepared in Example 2 was kneaded well and placed in a pot. The pot was placed in a water-filled water bath. The primary bath was carried out while maintaining at 98-102 ° C for 3 days using a temperature measuring device (KP3001, Ziraffe, China), and the water filled in the bath was supplemented so that the pottery could be kept over 80%. After the 1st bath, the 1st aging process was carried out while leaving at room temperature for 1 day. Subsequently, the secondary bath was performed under the same conditions as the primary bath for 1 day, and then the secondary aging process was performed under the same conditions as the primary aging for 1 day to produce an immune-enhanced gob (IYG-gami). .

<실시예 7> 면역 증진 고(膏) 제조<Example 7> Immunity-promoting high production

실시예 3에서 제조된 면역활성 증강용 한약재 조성물을 이용한 것을 제외하고 실시예 6과 동일한 방법으로 면역 증진 고(膏)를 제조하였다(M-IYG-gami).Immune-enhancing high (膏) was prepared in the same manner as in Example 6, except that the herbal composition for enhancing immune activity prepared in Example 3 was used (M-IYG-gami).

<실시예 8> 면역 증진 고(膏) 제조<Example 8> Immunity-promoting high production

실시예 4에서 제조된 면역활성 증강용 한약재 조성물을 이용한 것을 제외하고 실시예 6과 동일한 방법으로 면역 증진 고(膏)를 제조하였다(IYG-gami-F).Immune-promoting high (膏) was prepared in the same manner as in Example 6, except that the herbal medicine composition for enhancing immune activity prepared in Example 4 was used (IYG-gami-F).

<실시예 9> 면역 증진 고(膏) 제조<Example 9> Preparation of high immunity

실시예 5에서 제조된 면역활성 증강용 한약재 조성물을 이용한 것을 제외하고 실시예 6과 동일한 방법으로 면역 증진 고(膏)를 제조하였다(M-IYG-gami-F).Immune-enhancing high (膏) was prepared in the same manner as in Example 6, except that the herbal medicine composition for enhancing immune activity prepared in Example 5 was used (M-IYG-gami-F).

<실험예> 동물 실험을 통한 면역증진 효과<Experimental Example> Immunity enhancement effect through animal experiments

1-1. 실험 방법1-1. Experimental method

1) 동물1) Animal

체중이 약 170∼180 g의 Sprague Dawley계의 흰쥐(白鼠)를 항온항습 환경의 사육장(실내온도 24∼26℃, 습도 40∼60%)내에서 고형사료(Pellet, GMO, 한국)와 물을 충분히 공급하면서 1주일 이상 실험실 환경에 적응시킨 후 실험에 사용하였으며, 실험기간 동안에도 물과 고형사료를 자유롭게 섭취하도록 하였다.Sprague Dawley-based rats weighing about 170-180 g were fed solid feed (Pellet, GMO, Korea) and water in a breeding facility (room temperature 24-26 ° C, humidity 40-60%) in a constant temperature and humidity environment. Adapted to the laboratory environment for more than a week while supplying enough, it was used for experiments, and water and solid feed were freely consumed during the experiment.

2) 면역저하 유발2) Induced immune depression

면역저하 유발은 메토트렉세이트(Methotrexate, MTX)(Sigma, USA) 분말을 2mg/Kg 의 농도로 정하였으며, 전체 실험기간 20일 중 8일째부터 11일째 4일간 1회/1일 총 4회 구강 투여를 시행하였다.For immunosuppression, methotrexate (MTX) (Sigma, USA) powder was defined as a concentration of 2 mg / Kg. Oral administration was performed once a day for 4 days, once every 4 days from the 8th to the 11th of the 20th of the entire experimental period. Was implemented.

3) 군 분리 (n=5) 3) Group separation (n = 5)

실험군은 면역저하를 유발하지 않은 정상군(Normal), MTX 면역저하 유발 후 무처리한 대조군(Control), MTX 면역저하 유발 후 실시예 6 시료 투여된 실험군 A(IYG-gami), MTX 면역저하 유발 후 실시예 8 시료 투여된 실험군 B(IYG-gami-F), MTX 면역저하 유발 후 실시예 7 시료 투여된 실험군 C(M-IYG-gami), MTX 면역저하 유발 후 실시예 9 시료 투여된 실험군 D(M-IYG-gami-F)로 각각 나누었다.The experimental group was a normal group that did not induce immunosuppression (Normal), an untreated control group (Control) after inducing MTX immunosuppression, and an induction of MTX immunosuppression Example 6 Sample group administered experimental group A (IYG-gami), induced MTX immunosuppression After Example 8 Sample administration group B (IYG-gami-F), after administration of MTX immunosuppression Example 7 Sample administration group C (M-IYG-gami), after administration of MTX immunosuppression Example 9 sample administration group D (M-IYG-gami-F).

4) 시료 투여4) Sample administration

각 시료는 200mg/Kg 농도로 제조한 후 전체 실험기간(20일) 동안 음용수와 함께 투여하였다. Each sample was prepared at a concentration of 200 mg / Kg and then administered with drinking water for the entire experimental period (20 days).

5) 체중 및 비장무게 측정5) Weight and spleen weight measurement

체중은 전자 저울(Cass, China)을 이용하여 실험 1일째, 5일째, 10일째, 15일째, 20일째 측정하였다. 비장무게는 실험 종료 후 비장을 분리하여 측정하였다.Body weights were measured on the 1st, 5th, 10th, 15th, and 20th days of the experiment using an electronic balance (Cass, China). Spleen weight was measured by separating the spleen after the experiment.

6) 혈액 및 혈청학적 검사6) Blood and serological tests

채혈에 의하여 얻어진 혈액 중 약 100 μl를 EDTA-bottle에 넣은 후 곧바로 Multi species Hematology Analyser(950, Hemavet, USA)에 주입하여 Leukocytes, Erythrocytes, WBC, RBC, HGB, HCT를 측정하였다. 나머지 혈액은 고속원심분리기(Centricon T-42K, Italy)에서 3,500 rpm으로 20분간 시행하여 혈청을 분리하였으며, 혈청 분석으로는 AST, ALT를 Dri-chem 4000i(Fujifilm corp. Japan)으로 측정하였다.About 100 μl of blood obtained by blood collection was put into EDTA-bottle, and immediately injected into Multi species Hematology Analyser (950, Hemavet, USA) to measure Leukocytes, Erythrocytes, WBC, RBC, HGB, and HCT. The rest of the blood was separated for 20 minutes at 3,500 rpm in a high-speed centrifuge (Centricon T-42K, Italy), and serum was analyzed by Dri-chem 4000i (Fujifilm corp. Japan).

7) ELISA 측정7) ELISA measurement

① TNF-a① TNF-a

TNF-α 측정은 Rat TNF-α(Invitrogen, USA)를 사용하여 측정하였다. Rat TNF-α 가 coating된 microplate에 Rat TNF-α standard, serum, control 100 ㎕를 첨가하고 plate cover로 tapping한 후에 1분간 mixing하고 실온에 2시간 방치하였다. Washing solution 400 ㎕로 4회 washing 후 Rat TNF-α Biontin Conjugate 100 ㎕를 첨가하고 plate cover를 덮고 실온에 1시간 방치하였다. Washing solution 400 ㎕로 4회 washing 후 Streptavidin-HRP Working solution 100 ㎕를 첨가하고 plate cover를 덮고 실온에 30분 간 방치하였다. Washing solution 400 ㎕로 4회 washing 후 Stabilized Chromogen 100 ㎕를 첨가하고 plate cover를 덮고 실온(어두운 상태)에 30분간 방치하였다. Stop solution 100 ㎕를 plate에 넣고 발색반응을 중지시킨 후 microplate reader(EZ Read 400, Biochrom, US)로 450 ㎚에서 OD(Optical density)를 측정하였다. Standard curve를 만들어 sample의 TNF-α 양을 assay하였다.TNF-α was measured using Rat TNF-α (Invitrogen, USA). To the microplate coated with Rat TNF-α, 100 μl of Rat TNF-α standard, serum, and control were added, and after tapping with a plate cover, mixed for 1 minute and left at room temperature for 2 hours. After washing 4 times with 400 μl of Washing solution, 100 μl of Rat TNF-α Biontin Conjugate was added, the plate cover was covered, and left at room temperature for 1 hour. After washing 4 times with 400 μl of Washing solution, 100 μl of Streptavidin-HRP Working solution was added, the plate cover was covered, and left at room temperature for 30 minutes. After washing 4 times with 400 μl of Washing solution, 100 μl of Stabilized Chromogen was added, the plate cover was covered, and left at room temperature (dark) for 30 minutes. After adding 100 μl of Stop solution to the plate to stop the color reaction, OD (Optical Density) was measured at 450 nm with a microplate reader (EZ Read 400, Biochrom, US). A standard curve was created to assay the amount of TNF-α in the sample.

② Interleukin-2 (IL-2)② Interleukin-2 (IL-2)

IL-2 측정은 Rat IL-2(R&D Systems, USA)를 사용하여 측정하였다. Microplate)의 각 웰(Well)에 Assy Diluent RD1-21 50 ul을 넣고 Rat IL-2 standard, control, serum 50 ul를 첨가하고 plate cover로 tapping한 후에 1분간 mixing하고 실온에 2시간 방치하였다. Washing solution 400 ul로 5회 washing 후 Rat IL-2 conjugate 100 ul를 첨가하고 plate cover를 덮고 실온에 2시간 방치하였다. Washing solution 400 ul로 5회 washing 후 Substrate solution 100 ul를 첨가하고 plate cover를 덮고 실온(어두운 상태) 30분 간 방치하였다. Stop solution 100 ul를 plate에 넣고 발색반응을 중지시킨 후 microplate reader(EZ Read 400, Biochrom, US)로 450 ㎚에서 OD(Optical density)를 측정하였다.IL-2 was measured using Rat IL-2 (R & D Systems, USA). 50 ul of Assy Diluent RD1-21 was added to each well of the microplate), 50 ul of rat IL-2 standard, control, serum was added, and after tapping with a plate cover, mixed for 1 minute and left at room temperature for 2 hours. After washing 5 times with 400 ul of Washing solution, 100 ul of Rat IL-2 conjugate was added and the plate cover was covered and left at room temperature for 2 hours. After washing 5 times with 400 ul of Washing solution, 100 ul of Substrate solution was added, the plate cover was covered, and left at room temperature (dark condition) for 30 minutes. After adding 100 ul of Stop solution to the plate to stop the color reaction, OD (Optical density) was measured at 450 nm with a microplate reader (EZ Read 400, Biochrom, US).

③ Interleukin-6 (IL-6)③ Interleukin-6 (IL-6)

IL-6 측정은 Rat IL-6(R&D Systems, USA)를 사용하여 측정하였다. Microplate의 각 웰에 Assy Diluent RD1-21 50 ul을 넣고 Rat IL-10 standard, control, serum 50 ul를 첨가하고 plate cover로 tapping한 후에 1분간 mixing하고 실온에 2시간 방치하였다. Washing solution 400 ul로 5회 washing 후 Rat IL-10 conjugate 100 ul를 첨가하고 plate cover를 덮고 실온에 2시간 방치하였다. Washing solution 400 ul로 5회 washing 후 Substrate solution 100 ul를 첨가하고 plate cover를 덮고 실온(어두운 상태) 30분간 방치하였다. Stop solution 100 ul를 plate에 넣고 발색반응을 중지시킨 후 microplate reader(EZ Read 400, Biochrom, US)로 450 ㎚에서 OD(Optical density)를 측정하였다.IL-6 was measured using Rat IL-6 (R & D Systems, USA). 50 ul of Assy Diluent RD1-21 was added to each well of the microplate, and 50 ul of rat IL-10 standard, control, serum was added, and after tapping with a plate cover, mixed for 1 minute and left at room temperature for 2 hours. After washing 5 times with 400 ul of Washing solution, 100 ul of Rat IL-10 conjugate was added, the plate cover was covered, and left at room temperature for 2 hours. After washing 5 times with 400 ul of Washing solution, 100 ul of Substrate solution was added, the plate cover was covered, and left at room temperature (dark condition) for 30 minutes. After adding 100 ul of Stop solution to the plate to stop the color reaction, OD (Optical density) was measured at 450 nm with a microplate reader (EZ Read 400, Biochrom, US).

④ Immunoglobulin E (Ig E)④ Immunoglobulin E (Ig E)

Ig E 측정은 Rat Ig E Elisa Kit(Abcam, UK)를 사용하여 측정하였다. Microplate의 각 웰에 Ig E standard, control, serum 100 ㎕를 넣은 후 plate cover로 tapping한 후에 1분간 mixing하고 실온에 1시간 방치하였다. 1X Wash Buffer로 3회 washing 후 1X Enzyme-Antibody conjugate 100 ㎕를 첨가하고 plate cover를 덮고 실온(어두운 상태)에 1시간 방치하였다. 1X Wash Buffer로 3회 washing 후 TMB Substrate solution 100 ㎕를 첨가하고 plate cover를 덮고 실온(어두운 상태)에 10분간 방치하였다. Stop solution 100 ㎕를 plate에 넣고 발색반응을 중지시킨 후 microplate reader(EZ Read 400, Biochrom, US)로 450 ㎚에서 OD(Optical density)를 측정하였다.Ig E was measured using a Rat Ig E Elisa Kit (Abcam, UK). After adding 100 μl of Ig E standard, control, and serum to each well of the microplate, tapping with a plate cover, mixing for 1 minute, and allowed to stand at room temperature for 1 hour. After washing 3 times with 1X Wash Buffer, 100 µl of 1X Enzyme-Antibody conjugate was added, the plate cover was covered, and left at room temperature (dark) for 1 hour. After washing 3 times with 1X Wash Buffer, 100 µl of TMB Substrate solution was added, the plate cover was covered, and left at room temperature (dark condition) for 10 minutes. After adding 100 μl of Stop solution to the plate to stop the color reaction, OD (Optical Density) was measured at 450 nm with a microplate reader (EZ Read 400, Biochrom, US).

1-2. 통계처리1-2. Statistics processing

모든 측정값은 Excel statistic program(Microsoft, USA)을 이용하여 평균치와 표준오차(mean±standard error)로 표시하였고, 각 실험군 간의 통계학적 분석은 Window용 SPSS(SPSS, USA)를 사용하여 비모수적 방법으로 Mann-Whitney U test를 시행하였다. 각 실험군은 대조군에 비하여 α=0.05 수준(P<0.05)과 α=0.01 수준(P<0.01)에서 유의성을 검정하였다.All measured values were expressed as mean and standard error using the Excel statistic program (Microsoft, USA). Statistical analysis between each experimental group was non-parametric using SPSS for Windows (SPSS, USA). Mann-Whitney U test was performed. Each experimental group was tested for significance at α = 0.05 level (P <0.05) and α = 0.01 level (P <0.01) compared to the control group.

1-3. 실험결과1-3. Experiment result

1) TNF-α에 미치는 영향1) Effect on TNF-α

TNF-α 함량은 면역저하 유발 후 무처리한 대조군이 면역저하를 유발하지 않은 정상군에 비하여 유의한 증가를 나타내었다. 본 발명의 면역활성 증강용 한약재 조성물이 투여된 실험군 A~D는 모두 대조군에 비하여 유의하게 감소하였다(표 2 및 도 2).The TNF-α content showed a significant increase in the non-treated control group after induction of immunosuppression compared to the normal group that did not induce immunosuppression. All of the experimental groups A to D in which the herbal composition for enhancing the immune activity of the present invention was administered were significantly reduced compared to the control group (Table 2 and FIG. 2).

Figure 112018003770369-pat00004
Figure 112018003770369-pat00004

2. Interleukin-2 (IL-2)에 미치는 영향2. Effect on Interleukin-2 (IL-2)

IL-2는 대조군이 정상군에 비하여 유의한 증가를 나타내었으며, 실험군 모두 대조군에 비하여 유의한 감소를 나타내었다(표 3 및 도 3).In IL-2, the control group showed a significant increase compared to the normal group, and all of the experimental groups showed a significant decrease compared to the control group (Table 3 and FIG. 3).

Figure 112018003770369-pat00005
Figure 112018003770369-pat00005

3. Interleukin-6 (IL-6)에 미치는 영향3. Effect on Interleukin-6 (IL-6)

IL-6은 대조군이 정상군에 비하여 유의한 증가를 나타내었으며, 실험군 모두 대조군에 비하여 유의한 감소를 나타내었다(표 4 및 도 4).In IL-6, the control group showed a significant increase compared to the normal group, and all of the experimental groups showed a significant decrease compared to the control group (Table 4 and FIG. 4).

Figure 112018003770369-pat00006
Figure 112018003770369-pat00006

4. Immunoglobulin E (IgE)에 미치는 영향4. Effect on Immunoglobulin E (IgE)

IgE는 대조군이 정상군에 비하여 유의한 감소를 나타내었으며, 실험군 B, C, D는 대조군에 비하여 유의한 감소를 나타내었다(표 5 및 도 5).In IgE, the control group showed a significant decrease compared to the normal group, and the experimental groups B, C, and D showed a significant decrease compared to the control group (Table 5 and FIG. 5).

Figure 112018003770369-pat00007
Figure 112018003770369-pat00007

5. 비장무게에 미치는 영향5. Effect on spleen weight

본 발명의 한약재 조성물과 그 발효에 따라 비장무게 변화에 미치는 영향을 관찰한 결과, 정상군은 0.83±0.03 g, 대조군은 0.71±0.03 g으로 정상군에 비하여 대조군은 유의한 감소를 나타내었으며, IYG-gami군은 0.78±0.06 g, IYG-gami-F군은 0.78±0.05 g, M-IYG-gami군은 0.78±0.03 g, M-IYG-gami-F군은 0.81±0.02 g으로 대조군에 비하여 IYG-gami-F군은 유의한 증가를 나타내었다(표 6 및 도 6).As a result of observing the effect on the spleen weight change according to the herbal composition of the present invention and its fermentation, the normal group was 0.83 ± 0.03 g, the control was 0.71 ± 0.03 g, and the control group showed a significant decrease compared to the normal group, and IYG -gami group 0.78 ± 0.06 g, IYG-gami-F group 0.78 ± 0.05 g, M-IYG-gami group 0.78 ± 0.03 g, M-IYG-gami-F group 0.81 ± 0.02 g compared to the control group The IYG-gami-F group showed a significant increase (Table 6 and Figure 6).

Figure 112018003770369-pat00008
Figure 112018003770369-pat00008

6. 혈액 Leukocytes 함량 변화에 미치는 영향6. Effect on changes in blood Leukocytes content

본 발명의 한약재 조성물과 그 발효에 따라 혈액 Leukocytes 변화에 미치는 영향을 관찰한 결과, WBC와 Lymphocytes의 경우 대조군에 비하여 IYG-gami-F군은 유의한 증가를 나타내었다(표 7 및 도 7).As a result of observing the effect on changes in blood Leukocytes according to the herbal composition of the present invention and its fermentation, the IYG-gami-F group showed a significant increase in the case of WBC and Lymphocytes compared to the control group (Table 7 and FIG. 7).

Figure 112018003770369-pat00009
Figure 112018003770369-pat00009

7. 혈액 Erythrocytes 함량 변화에 미치는 영향7. Effect on blood Erythrocytes content change

본 발명의 한약재 조성물과 그 발효에 따라 혈액 Erythrocytes 변화에 미치는 영향을 관찰한 결과, 대조군에 비하여 MCV의 경우 실험군 모두 유의한 감소를 나타내었고, MCH의 경우 IYG-gami군은 유의한 감소를 나타내었다(표 8 및 도 8). As a result of observing the effect on the change of blood Erythrocytes according to the herbal composition of the present invention and its fermentation, in the case of MCV, the experimental group showed a significant decrease, and in the case of MCH, the IYG-gami group showed a significant decrease. (Table 8 and Figure 8).

Figure 112018003770369-pat00010
Figure 112018003770369-pat00010

8. 증체량 변화에 미치는 영향8. Effect on Change of Weight Gain

본 발명의 한약재 조성물과 그 발효에 따라 증체량 변화에 미치는 영향을 관찰한 결과, 정상군에 비하여 대조군은 15일째, 20일째에 유의한 감소를 보였으며, 대조군에 비하여 IYG-gami-F군은 15일째, 20일째에 유의한 증가를 보였고, M-IYG-ami-F군과 M-IYG-gami-F군은 15일째에 유의한 증가를 나타내었다(표 9 및 도 9).As a result of observing the effect on the weight gain change according to the herbal composition of the present invention and its fermentation, the control group showed a significant decrease on the 15th and 20th days compared to the normal group, and the IYG-gami-F group was 15 compared to the control group. On the first day, the 20th day showed a significant increase, and the M-IYG-ami-F group and the M-IYG-gami-F group showed a significant increase on the 15th day (Table 9 and FIG. 9).

Figure 112018003770369-pat00011
Figure 112018003770369-pat00011

9. 혈청 aminotransferase 함량 변화에 미치는 영향9. Effect on serum aminotransferase content change

익수영진고가미복합물(홍삼, 백복령, 생지황즙, 봉밀, 천문동, 맥문동, 구기자, 꽃송이버섯, 노루궁뎅이버섯, 초석잠), 복령피와 지황박을 배합한 익수영진고가미복합물, 그리고 발효에 따른 이들의 복합물이 면역기능에 미치는 영향을 혈청 aminotransferase 함량 변화로 관찰한 결과, aspartate aminotransferase (AST)의 경우, 정상군은 75.6±3.4 U/l, 대조군은 86.6±6.6 U/l, IYG-gami군은 83.8±3.2 U/l, IYG-gami-F군은 83.2±4.4 U/l, M-IYG-gami군은 88.6±9.7 U/l, M-IYG-gami-F군은 83.8±6.3 U/l를 나타내어 대조군과 실험군 모두 유의한 변화를 보이지 않았으며, alanine aminotransferase (ALT)의 경우, 정상군은 43.6±3.5 U/l, 대조군은 47.7±4.4 U/l, IYG-gami군은 42.6±3.2 U/l, IYG-gami-F군은 40.8±2.7 U/l, M-IYG-gami군은 46.2±7.0 U/l, M-IYG-gami-F군은 45.2±1.8 U/l를 나타내어 대조군과 실험군 모두 유의한 변화를 보이지 않았다(표 10 및 도 10).Iksuyoungjin Gogami Complex (Red Ginseng, Baekbokryeong, Raw Jihwang Juice, Bongmil, Cheonmun-dong, Macmun-dong, Gojija, Flowering Mushroom, Roe Mushroom Mushroom, Choseokjam), Iksu-young Jingogami Complex, and these according to fermentation As a result of observing changes in serum aminotransferase content of the complex of the immune function, aspartate aminotransferase (AST), 75.6 ± 3.4 U / l in the normal group, 86.6 ± 6.6 U / l in the control group, and IYG-gami group 83.8 ± 3.2 U / l, 83.2 ± 4.4 U / l for IYG-gami-F group, 88.6 ± 9.7 U / l for M-IYG-gami group, 83.8 ± 6.3 U / l for M-IYG-gami-F group In the alanine aminotransferase (ALT), 43.6 ± 3.5 U / l in the normal group, 47.7 ± 4.4 U / l in the control group, and 42.6 ± 3.2 U in the IYG-gami group. / l, 40.8 ± 2.7 U / l in the IYG-gami-F group, 46.2 ± 7.0 U / l in the M-IYG-gami group, and 45.2 ± 1.8 U / l in the M-IYG-gami-F group. None of the experimental groups showed significant changes ( Table 10 and Figure 10).

Figure 112018003770369-pat00012
Figure 112018003770369-pat00012

이상에서 본 발명의 구체예가 제시되어 있지만 본 발명이 상기에 한정되는 것은 아니며 본 발명의 기술 사상 범위 내에서 다양하게 변형 가능하고 이러한 변형은 하기한 본 발명의 청구범위에 속한다 할 것이다. Although specific examples of the present invention have been presented above, the present invention is not limited to the above, and various modifications are possible within the technical scope of the present invention, and such modifications will belong to the claims of the present invention described below.

Claims (3)

노루궁뎅이버섯, 꽃송이버섯, 홍삼, 백복령, 복령피, 천문동, 맥문동, 구기자, 초석잠, 생지황 즙액, 지황박 및 봉밀을 포함하는 면역활성 증강용 한약재 조성물로 이루어지되,
상기 면역활성 증강용 한약재 조성물은 조성물 총 중량에 대하여 노루궁뎅이버섯 1 내지 7 중량%, 꽃송이버섯 0.5 내지 5 중량%, 홍삼 2 내지 10 중량%, 백복령 3 내지 13 중량%, 복령피 0.5 내지 5 중량%, 천문동 0.5 내지 5 중량%, 맥문동 0.5 내지 5 중량%, 구기자 0.5 내지 5 중량%, 초석잠 0.5 내지 5 중량%, 생지황 즙액 25 내지 40 중량%, 지황박 10 내지 25 중량% 및 봉밀 25 내지 40 중량%를 포함하고,
상기 면역활성 증강용 한약재 조성물은 류코노스톡 메센테로이데스 서브스페시스 덱스트라니쿰(Leuconostoc mesenteroides subsp. dextranicum) 균주로 발효되며,
상기 발효는 36 내지 37℃에서 4 내지 6일 동안 실시되는 것을 특징으로 하는 면역활성 증강용 한약재 조성물.
It consists of a herbal medicine composition for enhancing immune activity, including roe deer mushroom, zinnia mushroom, red ginseng, Baekbokryeong, Bokryeongpi, Cheonmun-dong, McMun-dong, Gojija, Chosukjam, saengjihwang juice, Jihwang Park, and beeswax.
The composition for medicinal herbs for enhancing immunity is 1 to 7% by weight of yellow beetroot mushroom, 0.5 to 5% by weight of zinnia mushroom, 2 to 10% by weight of red ginseng, 3 to 13% by weight of Baengboknyeong, 0.5 to 5% by weight of Bokryeongpi , 0.5 to 5% by weight, Astronomical dong 0.5 to 5% by weight, 0.5 to 5% by weight wolfberry, 0.5 to 5% by weight Chomyeonjam, 25 to 40% by weight raw saengjuk juice, 10 to 25% by weight sulphate foil and 25 to 40 sealed seals Weight percent,
The herbal composition for enhancing the immune activity is fermented into Leuconostoc mesenteroides subsp. Dextranicum strain,
The fermentation is a herbal medicine composition for enhancing immune activity, characterized in that is carried out for 4 to 6 days at 36 to 37 ℃.
삭제delete 삭제delete
KR1020180004173A 2018-01-12 2018-01-12 Medicinal herbs composition for enhancing immune activity KR102098998B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180004173A KR102098998B1 (en) 2018-01-12 2018-01-12 Medicinal herbs composition for enhancing immune activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180004173A KR102098998B1 (en) 2018-01-12 2018-01-12 Medicinal herbs composition for enhancing immune activity

Publications (2)

Publication Number Publication Date
KR20190086092A KR20190086092A (en) 2019-07-22
KR102098998B1 true KR102098998B1 (en) 2020-04-22

Family

ID=67469052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180004173A KR102098998B1 (en) 2018-01-12 2018-01-12 Medicinal herbs composition for enhancing immune activity

Country Status (1)

Country Link
KR (1) KR102098998B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102553252B1 (en) * 2020-11-25 2023-07-12 농업회사법인 유한회사 나우리 Mnufacturing mathod of the nutrition snack with enhancing immune activity for companion dogs using Gyoungokgo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100518214B1 (en) * 2002-09-18 2005-09-30 주식회사 보성 Anticancer, immunopotentiatory and antioxidant composition containing Stachys Sieboldii extract
KR101374026B1 (en) * 2007-05-23 2014-03-12 롯데칠성음료주식회사 Fermented ginseng containing bio-conversed ginsenoside metabolites increased by co-fermentation of fungi and lactic acid bacteria
KR101016195B1 (en) 2009-04-15 2011-02-22 남영제약영농조합법인 Restorative herb medicine containing Gastrodia elata and preparation methods thereof
KR101198211B1 (en) 2010-03-12 2012-11-07 유한회사 해원 Manufacturing method of used the sea cucumbera restorative herb medicine
KR101496557B1 (en) * 2013-07-29 2015-02-25 이정복 Pharmaceutical composition for preventing or treating atopic dermatitis comprising extract of Sanguisorba officinalis and Hericium erinaceus
KR101868823B1 (en) * 2016-05-25 2018-08-02 농업회사법인 유한회사 나우리 The composition and manufacturing method of the blossoms hongsamsu okgo included in gyeongokgo

Also Published As

Publication number Publication date
KR20190086092A (en) 2019-07-22

Similar Documents

Publication Publication Date Title
CN104509864B (en) A kind of have nutritional health food improving gastrointestinal function and preparation method thereof
Diab et al. Effect of garlic, black seed and Biogen as immunostimulants on the growth and survival of Nile tilapia, Oreochromis niloticus (Teleostei: Cichlidae), and their response to artificial infection with Pseudomonas fluorescens
CN106666204A (en) Feed used for 72-100-week-old laying hens and capable of improving immune function and preparation method of feed
KR100860209B1 (en) A functional feed excipient using sulfur and manufacturing process of the same and a pork acquired therefore
CN109528777A (en) By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form
TWI459953B (en) A composition to improve cordycepin of solid-state cultivation
CN105146509B (en) A kind of method that probiotics stem of noble dendrobium ferment is produced using stem of noble dendrobium leaf
CN107041483A (en) A kind of laying cycle of laying hens feed for improving premunition and preparation method thereof
Bach et al. Use of polysaccharide extracted from Tremella fuciformis berk for control diabetes induced in rats.
Sharma et al. Medicinal, nutritional, and nutraceutical potential of Sparassis crispa s. lat.: A review
Wang et al. Process optimization for fermented siwu decoction by multi-index-response surface method and exploration of the effects of fermented siwu decoction on the growth, immune response and resistance to Vibrio harveyi of Pacific white shrimp (Litopenaeus vannamei)
CN114568602A (en) Traditional Chinese medicine compound for improving growth performance and organism immunity of broiler chickens and preparation method and application thereof
KR102098998B1 (en) Medicinal herbs composition for enhancing immune activity
CN110840924A (en) Application of rhizoma atractylodis stem and leaf extract
CN103948023A (en) Health foods for enhancing immunity and improving sleep and two-step fermentation preparation method thereof
KR102098999B1 (en) Medicinal herbs composition for improving cognitive function
Manayi et al. Immunomodulation effect of aqueous extract of the artist's conk medicinal mushroom, Ganoderma applanatum (Agaricomycetes), on the rainbow trout (Oncorhynchus mykiss)
CN105595351A (en) Nutritional product with steady blood sugar regulation function, preparation method and application thereof
CN114854604B (en) Ganoderma lucidum, high-concentration oral liquid containing ganoderma lucidum and preparation method thereof
CN108244632A (en) A kind of multifunctional solid health food and preparation method thereof
CN101185482A (en) Green environmental protection deer feed additive and preparation method thereof
KR101909936B1 (en) Food composition for enhancing function of immunity comprising fermented extract from material natural food by lactic acid bacteria and preparation method thereof
KR101275375B1 (en) Manufacturing Method of Cordyceps militaris Extracts And Health Assistance Food Comprising the Extracts
CN111249317A (en) Preparation method of myxomycete fermentation liquor, myxomycete fermentation liquor and application
CN101156654A (en) Environmental protection high calcium high protein deer feed additive

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
R401 Registration of restoration